SCYNEXIS Inc (NASDAQ:SCYX) CEO Marco Taglietti purchased 10,015 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was acquired at an average price of $1.01 per share, for a total transaction of $10,115.15. Following the completion of the purchase, the chief executive officer now owns 516,015 shares of the company’s stock, valued at $521,175.15. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
SCYX opened at $1.11 on Wednesday. The business’s fifty day moving average is $1.16 and its two-hundred day moving average is $1.34. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.99 and a current ratio of 4.99. The company has a market cap of $61.28 million, a price-to-earnings ratio of -2.27 and a beta of 2.31. SCYNEXIS Inc has a one year low of $0.35 and a one year high of $1.90.
SCYNEXIS (NASDAQ:SCYX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.02. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.06 million. SCYNEXIS had a negative return on equity of 141.28% and a negative net margin of 11,653.81%. On average, analysts predict that SCYNEXIS Inc will post -0.92 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning boosted its position in SCYNEXIS by 9.3% during the second quarter. Creative Planning now owns 139,000 shares of the company’s stock worth $182,000 after purchasing an additional 11,824 shares in the last quarter. Bailard Inc. purchased a new stake in SCYNEXIS during the first quarter worth $196,000. Renaissance Technologies LLC boosted its position in SCYNEXIS by 86.1% during the second quarter. Renaissance Technologies LLC now owns 475,315 shares of the company’s stock worth $623,000 after purchasing an additional 219,900 shares in the last quarter. Deutsche Bank AG purchased a new stake in SCYNEXIS during the fourth quarter worth $121,000. Finally, BlackRock Inc. boosted its position in SCYNEXIS by 152.0% during the second quarter. BlackRock Inc. now owns 854,880 shares of the company’s stock worth $1,121,000 after purchasing an additional 515,707 shares in the last quarter. Institutional investors own 31.55% of the company’s stock.
A number of research firms recently weighed in on SCYX. ValuEngine downgraded SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Saturday, May 18th. Zacks Investment Research downgraded SCYNEXIS from a “hold” rating to a “sell” rating in a research report on Wednesday, May 22nd. LADENBURG THALM/SH SH set a $6.00 target price on SCYNEXIS and gave the stock a “buy” rating in a research report on Friday, May 24th. Maxim Group set a $4.00 target price on SCYNEXIS and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Finally, Aegis assumed coverage on SCYNEXIS in a research report on Wednesday, July 31st. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. SCYNEXIS has an average rating of “Buy” and an average price target of $4.30.
SCYNEXIS, Inc is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections.
Featured Story: Why is Cost of Capital Important?
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.